Drug Trial Radar · NCT00340834
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Last checked: Nov 20, 2026Latest source record: Sep 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,292
Actual
Start
May 2006
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 21, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
Conditions
- Multiple Sclerosis
Interventions
Fingolimod 1.25 mgDrug
Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly. Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Fingolimod 0.5 mgDrug
Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly. Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Interferon β-1a 30 µgDrug
Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily. Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the StudyTime frame: Baseline to Month 12
Locations
170 sites in 18 countries. Site status is shown where the registry gives one.
North Central Neurology Associates, PC, 1809 Kress Street
Cullman, Alabama
Barrow Neurological Institute
Phoenix, Arizona
The Neurology Center, 3907 Waring Road, Suite 3
Oceanside, California
Associated Neurologists, PC, 69 Sand Pit Road, Suite 300
Danbury, Connecticut
Associated Neurologists of Southern CT, PC, 75 Kings Highway Cutoff
Fairfield, Connecticut
Yale University Multiple Sclerosis Center
New Haven, Connecticut
University of Florida Health Science Center
Jacksonville, Florida
Neurology Associates, PA, 301 N. Maitland Avenue, Suite A1
Maitland, Florida
University of Miami, Department of Neurology
Miami, Florida
Neurological Associates
Pompano Beach, Florida
Roskamp Institute, 2040 Whitfield Ave.
Sarasota, Florida
AMO Corporation
Tallahassee, Florida
Axiom Clinical Research of Florida, 2919 Swann Avenue, Suite 401
Tampa, Florida
University of South Florida, Department of Neurology
Tampa, Florida
The MS Center of Vero Beach
Vero Beach, Florida
University of Kansas Medical Center
Kansas City, Kansas
Mid America Neuroscience Institute, 8550 Marshall Drive, Suite 100
Lenexa, Kansas
University Physician Group, #1 Barnes-Jewish Hospital Plaza, Suite 16304
St Louis, Missouri
Neuroscience and Spine Center
Charlotte, North Carolina
Raleigh Neurology Associates, 1540 Sunday Drive
Raleigh, North Carolina
Neurology & Neuroscience Associates, Inc
Akron, Ohio
Northern Ohio Neuroscience, LLC
Bellevue, Ohio
Cleveland Clinic
Cleveland, Ohio
Oregon Neurology
Tualatin, Oregon
University of Pittsburgh, Department of Neurology
Pittsburgh, Pennsylvania
Absher Neurology, 274-A Commonwealth Drive
Greenville, South Carolina
Mountain Empire Neurological Associates, PC, 3183 West State Street, Suite 1201
Bristol, Tennessee
Advanced Neurosciences Institute
Franklin, Tennessee
Baylor College of Medicine
Houston, Texas
Private Practice, 3815 23rd Street
Lubbock, Texas
Integra Clinical Research, 4242 Medical Drive, Suite 6100
San Antonio, Texas
Swedish Neuroscience Institute
Seattle, Washington
Rockwood Clinic, P.S.
Spokane, Washington
West Virginia University Health Associates
Morgantown, West Virginia
Center for Neurological Disorders - Aurora St. Luke's Med Center
Milwaukee, Wisconsin
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Fundacion Lenox Cordoba
Córdoba, Argentina
Hospital J. M. Ramos Mejia
General Urquiza 609, Buenos Aires, Argentina
FLENI
Montaneses 2325, Buenos Aires, Argentina
Ineba
Guarda Vieja 4435, Capital Federal, Buenos Aires, Argentina
Showing 40 of 170 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.